Publications en collaboration avec des chercheurs de Universitat de València (15)

2024

  1. 3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial

    The Lancet, Vol. 403, Núm. 10437, pp. 1649-1659

  2. Clinicopathological and molecular predictors of [18F]FDG-PET disease detection in HER2-positive early breast cancer: RESPONSE, a substudy of the randomized PHERGain trial

    European Journal of Nuclear Medicine and Molecular Imaging

  3. Confirmatory study of the usefulness of quantum molecular resonance and microdissectomy for the treatment of lumbar radiculopathy in a prospective cohort at 6 months follow-up

    Scandinavian Journal of Pain, Vol. 24, Núm. 1

  4. Preventing alpelisib-related hyperglycaemia in HR+/HER2−/PIK3CA-mutated advanced breast cancer using metformin (METALLICA): a multicentre, open-label, single-arm, phase 2 trial

    eClinicalMedicine, Vol. 71

  5. Quantum Molecular Resonance Radiofrequency Disc Decompression and Percutaneous Microdiscectomy for Lumbar Radiculopathy

    Journal of Clinical Medicine, Vol. 13, Núm. 1

2021

  1. Randomized Prospective Study in Patients With Complex Regional Pain Syndrome of the Upper Limb With High-Frequency Spinal Cord Stimulation (10-kHz) and Low-Frequency Spinal Cord Stimulation

    Neuromodulation, Vol. 24, Núm. 3, pp. 448-458

2020

  1. Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial

    Breast Cancer Research, Vol. 22, Núm. 1

2019

  1. A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer

    Frontiers in Oncology, Vol. 9, Núm. APR

2018

  1. MSK1 regulates luminal cell differentiation and metastatic dormancy in ER + breast cancer

    Nature Cell Biology, Vol. 20, Núm. 2, pp. 211-221

  2. Erratum to: MSK1 regulates luminal cell differentiation and metastatic dormancy in ER+ breast cancer (Nature Cell Biology, (2018), 20, 2, (211-221), 10.1038/s41556-017-0021-z)

    Nature Cell Biology

  3. Paediatric research in Spain: Challenges and priorities. INVEST-AEP Platform

    Anales de Pediatria, Vol. 89, Núm. 5, pp. 314.e1-314.e6

  4. Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer

    Investigational New Drugs, Vol. 36, Núm. 5, pp. 848-859

2017

  1. Intrinsic subtypes and gene expression profiles in primary and metastatic breast cancer

    Cancer Research, Vol. 77, Núm. 9, pp. 2213-2221

2014

  1. The appropriate use of neurostimulation: Avoidance and treatment of complications of neurostimulation therapies for the treatment of chronic pain

    Neuromodulation, Vol. 17, Núm. 6, pp. 571-598

2012

  1. Cultural adaptation and validation of the painDETECT scale into Spanish

    Clinical Journal of Pain, Vol. 28, Núm. 3, pp. 243-253